Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11536106 | 0.89 | SMN1; SMN2 (0.41) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL4670943 | 0.84 | SMN1; SMN2 (0.37) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL510666 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL27788621 | 0.83 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL5232129 | 0.81 | SMN1; SMN2 (0.34) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL1078937 | 0.80 | SMN1; SMN2 (0.33) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL4675474 | 0.80 | ALDH1A1 (0.40) | CYP1A2HPGD | |
| SCHEMBL3397905 | 0.80 | RAB9A (0.33) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL20744563 | 0.79 | SMN1; SMN2 (0.37) | CYP2C19SMN1; SMN2NPC1RAB9AFDPS | |
| SCHEMBL2276496 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | CYP1A2 156/4885CYP3A4 236/4885CYP2C9 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.